Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy.

Although tremelimumab treatment did not reach statistical significance in overall survival at the planned second interim analysis in the phase III clinical trial in metastatic melanoma, follow-up analyses suggest that responses to tremelimumab are roughly comparable to those of ipilimumab, which has more Fc effector functions than tremelimumab [ 18 ].

also in 111,027 other papers